RxDoctor Payments Data

Thomas Nabity, MD

Otolaryngology · Grand Island, NENPI 1306924220

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for otolaryngology clinicians in NE, where the typical reported total is $741.

$829in general payments, 2019–2025

Across 42 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$192
  • Aerin Medical Inc.$159
  • Stryker$115
  • Intersect ENT, Inc.$65
  • Smith+Nephew$58
  • Sanofi$44
  • plus $197 from 8 others

What the payments were for

  • Food & beverage$80097%
  • Other$293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$829 in reported general payments places this provider in the 50th percentile of 86 otolaryngology providers in Nebraska.

See all otolaryngology providers in Nebraska

Medicare billing

Part B allowed, 2024
$111,109
Medicare patients
332
Services billed
1,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl124$3,909
SynthroidLevothyroxine Sodium36$2,540
Montelukast Sodium193$2,063
Levothyroxine Sodium149$1,766
Ipratropium Bromide36$1,250
Fluticasone Propionate73$1,089
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav85$1,045
Cefdinir34$841
Pantoprazole Sodium44$642
Omeprazole39$528
Doxycycline Hyclate38$479
Esomeprazole Magnesium16$469
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim47$444
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha29$357
Mupirocin36$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$26$2,54036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 86 otolaryngology providers in Nebraska.

Other otolaryngology in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →